170 related articles for article (PubMed ID: 14747476)
1. AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression.
Bernardin-Fried F; Kummalue T; Leijen S; Collector MI; Ravid K; Friedman AD
J Biol Chem; 2004 Apr; 279(15):15678-87. PubMed ID: 14747476
[TBL] [Abstract][Full Text] [Related]
2. AML1 stimulates G1 to S progression via its transactivation domain.
Bernardin F; Friedman AD
Oncogene; 2002 May; 21(20):3247-52. PubMed ID: 12082641
[TBL] [Abstract][Full Text] [Related]
3. Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins.
Lou J; Cao W; Bernardin F; Ayyanathan K; RauscherIII FJ; Friedman AD
Oncogene; 2000 May; 19(22):2695-703. PubMed ID: 10851069
[TBL] [Abstract][Full Text] [Related]
4. c-Myc overcomes cell cycle inhibition by CBFbeta-SMMHC, a myeloid leukemia oncoprotein.
Bernardin F; Yang Y; Civin CI; Friedman AD
Cancer Biol Ther; 2002; 1(5):492-6. PubMed ID: 12496475
[TBL] [Abstract][Full Text] [Related]
5. The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3.
Peterson LF; Boyapati A; Ranganathan V; Iwama A; Tenen DG; Tsai S; Zhang DE
Mol Cell Biol; 2005 Dec; 25(23):10205-19. PubMed ID: 16287839
[TBL] [Abstract][Full Text] [Related]
6. Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.
Kummalue T; Lou J; Friedman AD
Mol Cell Biol; 2002 Dec; 22(23):8278-91. PubMed ID: 12417730
[TBL] [Abstract][Full Text] [Related]
7. CBF beta-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells.
Cao W; Britos-Bray M; Claxton DF; Kelley CA; Speck NA; Liu PP; Friedman AD
Oncogene; 1997 Sep; 15(11):1315-27. PubMed ID: 9315100
[TBL] [Abstract][Full Text] [Related]
8. ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation.
Liu J; Lu W; Liu S; Wang Y; Li S; Xu Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Leuk Res; 2018 May; 68():15-21. PubMed ID: 29518627
[TBL] [Abstract][Full Text] [Related]
9. AML1/Runx1 recruits calcineurin to regulate granulocyte macrophage colony-stimulating factor by Ets1 activation.
Liu H; Holm M; Xie XQ; Wolf-Watz M; Grundström T
J Biol Chem; 2004 Jul; 279(28):29398-408. PubMed ID: 15123671
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation.
Zhang L; Fried FB; Guo H; Friedman AD
Blood; 2008 Feb; 111(3):1193-200. PubMed ID: 18003885
[TBL] [Abstract][Full Text] [Related]
11. Isoforms of the Ets transcription factor NERF/ELF-2 physically interact with AML1 and mediate opposing effects on AML1-mediated transcription of the B cell-specific blk gene.
Cho JY; Akbarali Y; Zerbini LF; Gu X; Boltax J; Wang Y; Oettgen P; Zhang DE; Libermann TA
J Biol Chem; 2004 May; 279(19):19512-22. PubMed ID: 14970218
[TBL] [Abstract][Full Text] [Related]
12. Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G1-S phase progression.
Keenan SM; Lents NH; Baldassare JJ
J Biol Chem; 2004 Feb; 279(7):5387-96. PubMed ID: 14645251
[TBL] [Abstract][Full Text] [Related]
13. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
[TBL] [Abstract][Full Text] [Related]
14. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
Vangala RK; Heiss-Neumann MS; Rangatia JS; Singh SM; Schoch C; Tenen DG; Hiddemann W; Behre G
Blood; 2003 Jan; 101(1):270-7. PubMed ID: 12393465
[TBL] [Abstract][Full Text] [Related]
15. The AML1/ETO fusion protein activates transcription of BCL-2.
Klampfer L; Zhang J; Zelenetz AO; Uchida H; Nimer SD
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14059-64. PubMed ID: 8943060
[TBL] [Abstract][Full Text] [Related]
16. Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases.
Joshi I; Minter LM; Telfer J; Demarest RM; Capobianco AJ; Aster JC; Sicinski P; Fauq A; Golde TE; Osborne BA
Blood; 2009 Feb; 113(8):1689-98. PubMed ID: 19001083
[TBL] [Abstract][Full Text] [Related]
17. A permissive role for phosphatidylinositol 3-kinase in the Stat5-mediated expression of cyclin D2 by the interleukin-2 receptor.
Moon JJ; Rubio ED; Martino A; Krumm A; Nelson BH
J Biol Chem; 2004 Feb; 279(7):5520-7. PubMed ID: 14660677
[TBL] [Abstract][Full Text] [Related]
18. The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP.
Izutsu K; Kurokawa M; Imai Y; Ichikawa M; Asai T; Maki K; Mitani K; Hirai H
Oncogene; 2002 Apr; 21(17):2695-703. PubMed ID: 11965542
[TBL] [Abstract][Full Text] [Related]
19. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
[TBL] [Abstract][Full Text] [Related]
20. c-Jun N-terminal kinase mediates AML1-ETO protein-induced connexin-43 expression.
Gao FH; Wang Q; Wu YL; Li X; Zhao KW; Chen GQ
Biochem Biophys Res Commun; 2007 May; 356(2):505-11. PubMed ID: 17367753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
